|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KLF6 IVS 1-27 G > A may not be associated with cancer susceptibility, especially the susceptibility of unselected prostate cancer.
|
29970714 |
2018 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
These observations provide additional evidence for a role of PACAP and PAC1 R in the events determining the outcome of PCa.
|
16888207 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, a common germline polymorphism in the KLF6 gene associated with increased prostate cancer risk in a large multi-institutional study of 3411 men results in increased expression of KLF6-SV1.
|
19097929 |
2009 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Most recently, we identified a common KLF6 germ line single nucleotide polymorphism that is associated with an increased relative risk of prostate cancer and the increased production of three alternatively spliced, dominant-negative KLF6 isoforms.
|
15994951 |
2005 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data indicate that acetylation may regulate KLF6 function, and its loss in some tumor-derived mutants could contribute to its failure to suppress growth in prostate cancer.
|
16230382 |
2005 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The rs3750861 affects expression of KLF6 splicing variants in prostate cancer and we found that its rare allele is associated with reduced lung cancer risk (odds ratio, 0.5; 95% CI, 0.3-0.8).
|
17223258 |
2007 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results do not support the suggested association of KLF6 IVS1 -27G>A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.
|
17125911 |
2007 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Kruppel-like factor 6 (KLF6) is a ubiquitous zinc finger tumor suppressor that is often mutated in prostate cancer.
|
15057748 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor KLF6 gene.
|
18190704 |
2008 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Klf6 protein levels significantly decreased with progression in the TRAMP model of prostate cancer (P < 0.05), but there was no difference in Klf6 promoter methylation.
|
22782870 |
2013 |
|
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Kidney and prostate cancers are leading causes of death in the world, and accumulating evidence suggests that tumor suppressor gene, Krüppel-like factor 6 (KLF6), plays an important role in both the development and the progression of cancer.
|
18719336 |
2008 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These include the ELAC2 (HPC2), MSR1, and RNASEL (HPC1) genes that have germline mutations in familial prostate cancer; AR, ATBF1, EPHB2 (ERK), KLF6, mitochondria DNA, p53, PTEN, and RAS that have somatic mutations in sporadic prostate cancer; AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR that have germline genetic variants associated with either hereditary and/or sporadic prostate cancer; and ANXA7 (ANX7), KLF5, NKX3-1 (NKX3.1), CDKN1B (p27), and MYC that have genomic copy number changes affecting gene function.
|
16267836 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Whereas TP53 mutations typical of prostate cancer were found at a frequency consistent with the literature, no KLF6 mutations were found in any of the tumour samples nor in the three prostate cancer cell lines.
|
12915879 |
2003 |
|
Stomach Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
In summary, these data suggest that KLF6 gene is a direct target of miR-181a and miR-181a functions as an oncomir in gastric cancer by repressing the expression of tumor suppressor KLF6.
|
22581522 |
2012 |
|
Stomach Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The IVS1 -27G/A polymorphism of KLF6 has been investigated, which can influence susceptibility to gastric cancer and disease outcome.
|
18190240 |
2008 |
|
Stomach Carcinoma
|
0.360 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.
|
21538018 |
2011 |
|
Stomach Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Thus, in this Chinese population the KLF6 IVS1 -27AA genotype was associated with a decreased risk of gastric cancer and with cancer stage.
|
21309496 |
2011 |
|
Stomach Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
To determine whether genetic alterations of KLF6 gene are involved in the development and/or progression of gastric cancer, we have screened a set of 80 sporadic gastric cancers for mutations and allele loss of the KLF6 gene.
|
15824733 |
2005 |
|
Stomach Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
An inverse association was observed between miR‑18b and KLF6 mRNA levels in GC tissues.
|
30628682 |
2019 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that quantification of total and spliced forms of KLF6 may provide a new and useful supplementary molecular tool for grading glioma.
|
20545576 |
2010 |
|
Glioma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Relative to normal human brain, PAC1-R expression is significantly upregulated in glioma, particularly oligodendrogliomas.
|
10867818 |
2000 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
We investigated PAC-1 as a single agent and in combination with TMZ against glioma cells in culture and in orthotopic rodent models of glioma.
|
29113289 |
2017 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Additionally, procaspase-3 expressing glioma and meningioma cell lines were sensitive to the apoptotic effects of PAC-1 at biologically relevant exposures achievable in cancer patients.
|
30859090 |
2019 |